Nuclear FAK Promotes Cell Proliferation and Survival through FERM-Enhanced p53 Degradation

FAK is known as an integrin- and growth factor-associated tyrosine kinase promoting cell motility. Here we show that, during mouse development, FAK inactivation results in p53- and p21-dependent mesodermal cell growth arrest. Reconstitution of primary FAK−/−p21−/− fibroblasts revealed that FAK, in a...

Full description

Saved in:
Bibliographic Details
Published in:Molecular cell Vol. 29; no. 1; pp. 9 - 22
Main Authors: Lim, Ssang-Taek, Chen, Xiao Lei, Lim, Yangmi, Hanson, Dan A., Vo, Thanh-Trang, Howerton, Kyle, Larocque, Nicholas, Fisher, Susan J., Schlaepfer, David D., Ilic, Dusko
Format: Journal Article
Language:English
Published: United States Elsevier Inc 18-01-2008
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:FAK is known as an integrin- and growth factor-associated tyrosine kinase promoting cell motility. Here we show that, during mouse development, FAK inactivation results in p53- and p21-dependent mesodermal cell growth arrest. Reconstitution of primary FAK−/−p21−/− fibroblasts revealed that FAK, in a kinase-independent manner, facilitates p53 turnover via enhanced Mdm2-dependent p53 ubiquitination. p53 inactivation by FAK required FAK FERM F1 lobe binding to p53, FERM F2 lobe-mediated nuclear localization, and FERM F3 lobe for connections to Mdm2 and proteasomal degradation. Staurosporine or loss of cell adhesion enhanced FERM-dependent FAK nuclear accumulation. In primary human cells, FAK knockdown raised p53-p21 levels and slowed cell proliferation but did not cause apoptosis. Notably, FAK knockdown plus cisplatin triggered p53-dependent cell apoptosis, which was rescued by either full-length FAK or FAK FERM re-expression. These studies define a scaffolding role for nuclear FAK in facilitating cell survival through enhanced p53 degradation under conditions of cellular stress.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Present address: Dept. of Graduate Studies, Harvard University, Boston, MA.
Present address: PrimeGen Biotech LLC, 213 Technology Dr., Irvine, CA 92618
Present address: StemLifeLine Inc., San Carlos, CA 94070
ISSN:1097-2765
1097-4164
DOI:10.1016/j.molcel.2007.11.031